James Sales, MD
Child & Adolescent Psychiatry · Rock Island, ILNPI 1902885569
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,951 of the $4,427 with a category attached, or 89.2%. It is spread thinly across 20 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $56.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$824
- AbbVie$624
- Neurocrine Biosciences, Inc.$413
- Jazz Pharmaceuticals Inc.$339
- Alkermes, Inc.$287
- Harmony Biosciences LLC$281
- plus $2K from 14 others
What the payments were for
- Food & beverage$3,95189%
- Education$47611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $824 |
| AbbVie(2 entities) | 34 | $624 |
| Neurocrine Biosciences, Inc. | 5 | $413 |
| Jazz Pharmaceuticals Inc. | 3 | $339 |
| Alkermes, Inc. | 3 | $287 |
| Harmony Biosciences LLC | 3 | $281 |
| Axsome Therapeutics, Inc. | 2 | $250 |
| Eisai Inc. | 2 | $215 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $214 |
| Otsuka America Pharmaceutical, Inc. | 2 | $177 |
| SK Life Science, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Supernus Pharmaceuticals, Inc. | 3 | $120 |
| Idorsia Pharmaceuticals US Inc | 2 | $110 |
| Argenx US, Inc. | 1 | $96 |
| Tris Pharma Inc | 1 | $79 |
| Lilly USA, LLC | 1 | $60 |
| Corium, LLC | 1 | $60 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,427 in reported general payments places this provider in the 90th percentile of 124 child & adolescent psychiatry providers in Illinois.
See all child & adolescent psychiatry providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 16 | $41,103 |
| RexultiBrexpiprazole | 12 | $19,898 |
| Paliperidone ErPaliperidone | 13 | $12,467 |
| Duloxetine Hcl | 149 | $7,070 |
| Ziprasidone Hcl | 58 | $4,712 |
| Aripiprazole | 81 | $4,386 |
| Bupropion XlBupropion Hcl | 146 | $3,833 |
| Divalproex Sodium ErDivalproex Sodium | 27 | $3,016 |
| Methylphenidate ErMethylphenidate Hcl | 29 | $2,532 |
| Adderall XrDextroamphetamine/Amphetamine | 11 | $2,316 |
| Lamotrigine | 156 | $2,167 |
| Quetiapine Fumarate | 171 | $2,129 |
| Temazepam | 25 | $1,778 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 55 | $1,624 |
| Sertraline Hcl | 175 | $1,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $13 | $41,10316 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $177 | $19,89812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 124 child & adolescent psychiatry providers in Illinois.
Other child & adolescent psychiatry in Rock Island
- Fareha MalikElgin$57K
- Gregory TeasHoffman Estates$36K
- Martins AdeoyeOrland Park$10K
- Daniel MartinezLombard$8K
- Khalid ArshadKankakee$8K
- Talat GhausHinsdale$6K
- Walter PedemonteOak Park$5K
- Shazia TayyabLibertyville$5K
- Bradley PechterMelrose Park$5K
- Birju PatelKenilworth$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.